BioRestorative Therapies, Inc. (BRTX)

Over the past six months, several events have impacted BRTX's stock price. In November 2025, the company reported its Q3 financial results, noting a revenue decrease and an increased net loss, while strengthening its financial position through a registered direct offering and a private placement. In February 2026, BioRestorative Therapies completed the enrollment of 99 patients in its Phase 2 trial for BRTX-100 and reported a positive outcome from a Type B meeting with the FDA regarding BRTX-100. In March 2026, the company issued a letter to shareholders, highlighting significant milestones, and reported expanded Phase 2 blinded data for BRTX-100. In April 2026, BioRestorative Therapies announced a strategic collaboration with 203 Creates and a strategic partnership with Dr. David J. Goldberg for the BioCosmeceutical platform and presented new data at ISCT 2026. In May 2026, the company reported expanded Phase 2 blinded dataset for BRTX-100. Despite these advancements, the company's share price experienced a significant decline.

There is no specific information available in the provided search results regarding demand seasonality for BioRestorative Therapies, Inc.'s products and services.

BioRestorative Therapies, Inc. is a biotechnology company focused on developing therapeutic products using cell and tissue protocols, primarily involving adult stem cells. The company operates within the Biotechnology industry and its core business revolves around regenerative medicine programs. Its major products and development programs include the brtxDISC™ Program, which is developing BRTX-100 for chronic lumbar disc disease and has received FDA IND clearance for chronic cervical discogenic pain, the Metabolic Program (ThermoStem®), which focuses on developing cell-based therapy candidates to target obesity and metabolic disorders, and the BioCosmeceutical Platform, which produces cell-based secretome for aesthetic applications.

BioRestorative Therapies, Inc. is headquartered in Melville, New York, United States. The Phase 2 clinical trial for BRTX-100 has been conducted across 15 U.S. sites. The company's BioCosmeceutical products are formulated and manufactured in its cGMP ISO-7 certified clean room. BioRestorative Therapies has also engaged in research collaborations with entities such as Pfizer, Rohto Pharmaceutical, and the University of Pennsylvania. The Japanese Patent Office has issued a Notice of Allowance for the company's ThermoStem® platform.

Direct information specifically detailing BioRestorative Therapies, Inc.'s brand reputation is limited in the provided search results. However, the company's strategic partnerships and research collaborations could positively influence its scientific and business reputation. The consistent reporting of positive blinded Phase 2 data for BRTX-100 also contributes to a favorable reputation within the scientific and medical communities. Conversely, the significant decline in stock price over the past year could negatively impact investor confidence and the company's financial reputation.

BioRestorative Therapies, Inc. has a diverse ownership structure. Institutional owners hold a total of 409,931 shares, accounting for 4.56% of the total shares. Key individual owners include Lance Alstodt and Francisco Silva, with insiders collectively holding 13.60% of the stock. The general public holds 83.2% of the shares. Shareholders have experienced substantial dilution in the past year, with total shares outstanding increasing by 239.5%.